Aralez to Acquire From AstraZeneca U.S. Rights to Beta Blocker Toprol-XL®
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- Wall St edges up as AI enthusiasm eases worries over higher oil prices, yields
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil slides as US-Iran truce hopes outweigh Houthi attacks on Saudi Arabia
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- US and Iran discuss phased deal to reopen Hormuz and end US blockade, sources say
Guggenheim Remains Positive on Aralez Pharma (ARLZ) Amid Toprol-XL Deal with AstraZeneca (AZN)
October 4, 2016 8:52 AM EDTGuggenheim affirms Aralez Pharmaceuticals Inc. (Nasdaq: ARLZ) with a Buy rating and $12 price target after the company announced it will acquire the U.S. rights... More
